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Dr Riccodoi:10.1016/j.jtcvs.2005.07.029Background: The purpose of this study was to assess the overall short-term outcome
of stent-graft repair for thoracic aortic disease in France between June 1999 and
May 2001.
Methods: This retrospective study was designed by the French National Health
Insurance Fund for Salaried Workers. To ensure objectivity, data were retrieved at
each center and checked by a team of medical advisors.
Results: Between June 1999 and May 2001, a total of 166 stent-graft repairs for
thoracic aortic disease were performed in 166 patients, mainly by surgeons in the
operating room (88%). Patients were classified according to the American Society
of Anesthesiologists as status I or II in 24% of cases, status III in 56%, and status
IV or V in 20%. The diameter of the thoracic aneurysm was less than 50 mm in 17%
of cases. Seventeen patients (10%) died during the first 3 months, including 8 within
the first 30 days after the procedure. A total of 49 complications were noted in 34
patients (20.5%). Endoleaks occurred in 27 patients (16.3%), including 8 that
necessitated further treatment. Other stent-related complications included rupture
(n  3), aortoesophageal or tracheal fistula (n  3), paraplegia (n  6), stent
migration (n 2), visceral embolism (n 5), and cerebral embolism (n 2). There
were 14 delivery-related complications (8%) at the catheterization site. Non–stent-
related complications occurred in 14 (8%).
Conclusions: This nationwide study demonstrates that stent-graft repair for thoracic
aortic disease can be performed with acceptable postoperative morbidity. However,
it is not a risk-free procedure and should continue to be used in an investigative
setting.
Endovascular repair is a potentially beneficial alternative to conventional opensurgery for the entire spectrum of thoracic aortic disease (TAD). Even whenperformed at specialized centers, conventional open repair is associated with
significant morbidity, including paraplegia, and 30-day mortality rates from 5% to
20% in degenerative aneurysm and 6% to 67% in type B aortic dissection.1-8
Use of endovascular techniques has progressed more slowly for TAD than for
infrarenal aortic aneurysm. However, the use of endovascular stent-graft procedures
for TAD has increased since the first procedures were reported first by Volodos and
colleagues9 in 1991 and then by Dake and colleagues10 in 1994.
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Healthcare Products, in compliance with European Direc-
tive 93/42 EEC of June 1993, conducted a thorough study to
evaluate the safety of aortic stent grafts.11 In 2002, the
French National Health Insurance Fund for Salaried Work-
ers undertook an exhaustive nationwide survey to evaluate
postoperative complications after placement of stent grafts
for abdominal aortic aneurysm and TAD. The results of the
survey concerning abdominal aortic aneurysm were pub-
lished in 2003.12 The purpose of this article is to describe
the findings concerning the overall short-term outcome of
stent-graft repair for TAD in France between June 1999 and
May 2001.
Patients and Methods
Study Design
This study was designed to allow analysis independent of admin-
istrative or commercial interests. It was conducted by a team of
medical advisors from the French National Health Insurance Fund
for Salaried Workers. Medical advisors are physicians responsible
for overseeing reimbursements. No medical advisor investigated
an institution where he or she had formerly practiced.
Data Collection
Data were collected from the medical charts of all patients who
underwent stent-graft repair for TAD in France from June 1, 1999,
to May 31, 2001. Patients were identified by using the list of all
centers performing vascular surgery, interventional radiology, or
cardiology in France. In addition, the computerized PMSI (Le
Programme de Médicalisation du Système d’Information ) coding
system (diagnosis-related groups) was searched to identify insti-
tutions caring for patients with TAD. The key words for the search
included aortic aneurysm as the principal diagnosis in association
with 10 International Classification of Diseases codes (171.0 to
171.9) and the so-called surgical homogenous patient groups in the
diagnosis category 05 (homogenous patient groups 158, 159, 160,
168, and 172). To further ensure that no procedure was over-
TABLE 1. Etiology of thoracic aortic disease treated with
stent grafts in France from June 1, 1999, to May 31, 2001
Etiology No. of patients %
Degenerative aortic aneurysm 90 53
Type B chronic dissecting aneurysm 33 20
Traumatic pseudoaneurysm 17 11
Aortic ulcer with intramural hematoma 23 14
Abbreviations and Acronyms
ASA American Society of Anesthesiologists
CI  95% confidence interval
TAD thoracic aortic diseaseSeptic aortic aneurysm 3 2
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device vigilance departments to obtain a list of all reported devices
and accidents and consulted compulsory registers for procedures
performed in operating rooms and radiology suites.
Scope of Data
All data concerning procedures involving insertion or ablation of a
stent graft for TAD were recorded, including clinical setting,
patient characteristics, TAD features, clinical findings, and post-
operative outcome. For adverse outcomes, a distinction was made
between stent- or procedure-related events and non–stent-related
complications.
Statistical Analysis
Statistical analysis was performed with GraphPad software
(GraphPad, San Diego, Calif). Variables were cross-checked, and
queries concerning missing or aberrant data were sent to regional
project directors. Percentages were calculated with 95% confi-
dence interval (CI). Life-table analysis was performed by using the
Kaplan-Meier method with 95% confidence interval.
Results
During the 2-year study period, 166 endovascular stent-
graft repairs for TAD were performed in 29 centers. The
number of stent grafts inserted per center was 1 at 8 centers,
2 to 5 at 17 centers, and 6 to 15 at 4 centers.
TABLE 2. Maximum diameter of 126 thoracic aortic aneu-
rysms* treated with stent grafts in France from June 1,
1999, to May 31, 2001
Aneurysm diameter No. of patients %
50 mm 21 17
50-59 mm 27 21
60 mm 78 62
Total 126 100
*Forty patients (24%) with trauma or aortic ulcer were excluded.
TABLE 3. Type of aortic stent grafts used in patients un-
dergoing endovascular repair for thoracic aortic disease in
France from June 1, 1999, to May 31, 2001
Stent-graft model No. of patients %
Excluder tag (Gore*) 88 53
Talent (Medtronic†) 52 31
Stenford (Stenford‡) 6 4
AneuRx (Medtronic) 3 1.5
Vanguard II (Boston Scientific§) 1 0.5
Custom-made by surgeon 16 10
Total 166 100
*W. L. Gore & Associates, Inc (Flagstaff, Ariz). †Medtronic, Inc (Minneap-
olis, Minn). ‡SARL (Paris, France). §Boston Scientific (Natick, Mass).
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Most patients, ie, 86% (n  142), were men. The mean age
was 69  15 years (range, 20-91 years). American Society
of Anesthesiologists (ASA) scores were determined on the
basis of associated risk factors in 129 patients (78%). There
were 31 patients (24%) with ASA status I or II, 72 (56%)
with ASA status III, and 26 (20%) with ASA status IV. The
overall median duration of hospitalization was 10 days
TABLE 4. Concomitant procedures (n  39) in patients
undergoing stent-graft repair for thoracic aortic disease in
France from June 1, 1999, to May 31, 2001
Procedure
No. of
Patients %
Transposition of the left subclavian
artery*
15 9
Repair of infrarenal abdominal aortic
aneurysm
8 5
Aortic or iliofemoral bypass 9 5.5
Iliac angioplasty (stenting) 3 1.7
Miscellaneous (trauma patients) 4 2.3
Total 39 23.5
*In addition, 4 patients had the left subclavian artery covered but not
transposed.
TABLE 5. Postoperative mortality as a function of etiology
in patients undergoing stent-graft repair for thoracic aortic
disease in France from June 1, 1999, to May 31, 2001
Etiology
No. of
patients
No. of
deaths %
Degenerative aortic aneurysm 90 6 6.6
Type B chronic dissecting aneurysm 33 5 15.2
Traumatic pseudoaneurysm 17 1 5.8
Aortic ulcer with intramural
hematoma
23 3 13.1
Septic aortic aneurysm 3 2 66.6
Total 166 17 100
Mortality corresponds to deaths occurring during the postoperative period.
TABLE 6. Mortality and morbidity, excluding endoleaks, as
repair for thoracic aortic disease
Status No of patients Deaths, n (%)
ASA I and II 31 0 (0)
ASA III 72 11 (15.3)
ASA IV and V 26 4 (15.4)
ASA unknown 37 2 (5.4)
Total 166 17 (10.2)
ASA, American Society of Anesthesiologists. In this series, 17 patients die
significantly lower in patients with ASA status I and II as compared with AS
and non–stent-related complications were not significantly different in patients
The Journal of Thoraci(range, 5-64 days). As shown in Table 1, the most common
type of TAD was asymptomatic degenerative aneurysm, in
53% of cases (n  90). Patients with chronic dissecting
aneurysm (n  33) presented no complications before
stent-graft insertion, but 4 had thoracic pain without
hemothorax.
Preoperative Workup
All 166 patients underwent preoperative imaging with spiral
computed tomographic scan. In addition, digitized angiog-
raphy with placement of a graduated catheter in the thoracic
aorta was performed in 127 cases (77%). All lesions were
located in the descending thoracic aorta. As shown in Table
2, the maximum aneurysm diameter, excluding patients
with trauma (n  17) and aortic ulceration (n  23), was
less than 50 mm in 21 patients (17%).
Stent Grafts and Implantation Procedures
As shown in Table 3, 6 different stent-graft models were
used. All commercially available devices used in this study
had received the CE mark. Implantation was performed in
an operating room equipped with a C-arm in 147 cases
(88%) and in a radiology suite in 19 cases (12%). The
procedure involved first-time stenting in 160 cases (96%)
and repeat stenting in 6 cases (3.6%). As shown in Table 4,
stent-graft repair was associated with other procedures in 39
patients (23.5%). Concomitant transposition of the left sub-
clavian artery was required in 15 patients (9%) who had
aneurysms with short necks arising near the origin of the
subclavian artery. Concomitant aortic or iliac bypass was
needed to allow implantation of the stent graft in 9 patients
(5.5%). Concomitant infrarenal abdominal aortic aneurysm
repair was performed in 8 patients (5%).
Immediate Complications
Thirty-day follow-up data were available for 163 patients
(98%; CI, 95%-99%), including angiography, computed
tomography with helical 3-dimensional reconstructions, and
plain chest radiography. In the first 30 days, there were 8
nction of the ASA score in patients undergoing stent-graft
Procedure- or stent-related
complications, n (%)
Non–stent-related
complications, n (%)
5 (6.1) 1 (3.2)
17 (23.6) 6 (8.3)
6 (23.1) 5 (19.2)
7 (18.9) 2 (5.4)
35 (21.1) 14 (8.4)
34 patients had 49 complications (see Table 9 for details). Mortality was
tus III to V (P .02). Procedure-related or stent graft–related complicationsa fu
d, and
A stawith ASA status I or II compared with ASA status III to V.
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erative complications occurred during hospitalization be-
yond the first 30 days. In all, 17 patients (10%; CI, 6%-16%)
died in the hospital. Tables 5 and 6 show analysis of
mortality as a function of etiology and ASA score, respec-
tively. Table 7 shows analysis of mortality and procedure-
or stent-related morbidity, including type I endoleaks, as a
function of the extent of aorta covered by the stent graft.
Table 8 shows mortality and morbidity as a function of the
diameter of the thoracic aneurysm. The percentage of com-
plications with each of the stent-graft models was compa-
rable (P  .04). Survival based on life-table analysis was
86%  6% at 6 months (Figure 1).
Table 9 summarizes the failures and complications ob-
served. Endoleak occurred in 27 cases (16.3%; 95 CI, 11%-
22%), including 6 type I endoleaks that necessitated further
treatment: conversion to open repair in 1 case and repeat
stent grafting in 5 cases. These type I endoleaks were related
to suboptimal proximal landing zones of 10 to 15 mm in
length with an angulation of 60° or more from the transverse
arch. In addition, 3 type III endoleaks occurred between 2
stent grafts with an angulation of 60° to 80° in the descend-
ing thoracic aorta. Finally, 18 type II endoleaks were diag-
nosed on postoperative computed tomographic scans per-
formed within the first postoperative month and were left
untreated. In addition to endoleaks, there were 49 compli-
cations (29%; CI, 23%-37%) in 34 patients (20%; CI, 15%-
TABLE 7. Mortality and procedure- or stent-related morbidi
of aorta covered by the stent graft in patients undergoing
Extent of aorta covered* No. of patients Deaths, n
A 23 3 (13.1
B 61 4 (6.5)
C 35 2 (5.7)
B  C 40 6 (15.0
D 7 2 (28.5
Total 166 17 (10.2
*A, distal arch and proximal descending aorta; B, middle third of the des
category above with concomitant open repair of abdominal aortic aneury
TABLE 8. Mortality and morbidity as a function of the diam
in France from June 1, 1999, to May 31, 2001
Aneurysm diameter Patients, n (%) Deaths, n (
50 mm 21 (17) 1 (4.7%)
50-59 mm 27 (21) 2 (7.4)
60 mm 78 (62) 10 (12.8)
Total 126 13 (10.3)
Forty patients (24%) with aortic trauma or aortic ulcer were excluded. Mo
(TAA) less than 50 mm in diameter (4.7%) was not significantly lower than that
134 The Journal of Thoracic and Cardiovascular Surgery ● Janu27%). Thirty-five complications were related to the stent
graft or procedure, and 14 were not stent related. The stent-
or procedure-related complications were rupture in 3 cases,
aortoesophageal or tracheal fistula resulting from stent-graft
insertion in 3, paraplegia in 6, visceral embolism in 5, stent
migration with visceral ischemia in 2, cerebral embolism in
2, and catheterization-site complications in 14, including
iliac artery perforation in 5 cases and iliac thrombosis or
peripheral embolism in 9 cases. All 6 cases of paraplegia
(3.6%; CI, 1.5%-7.9%), including 5 that were fatal, oc-
curred within 48 hours after the procedure. Three cases
occurred in patients with extensive degenerative aneurysm
of the descending aorta with concomitant open repair of an
infrarenal aortic aneurysm. Three other cases occurred in
patients with type B dissecting aneurysms with a stent graft
covering proximal entry tears in the descending thoracic
aorta. Paraplegia was also associated with other major com-
plications in 5 patients (Table 9). Spinal drainage was not
used in these patients because in 1999 to 2001, there was no
evidence that cerebrospinal fluid drainage was necessary in
these patients.10,13 Although no definitive statement about
the comparative risks of spinal cord ischemia with open
repair is possible, this study suggests that even if the risk of
spinal cord ischemia with thoracic stent graft is low, these
patients should have cerebrospinal fluid drainage and pre-
vention of hypotension, as used in open repair. In this series,
cluding type I and III endoleaks, as a function of the extent
vascular repair for thoracic aortic disease
Procedure- or stent-related
complications, n (%) Type I endoleaks, n (%)
6 (26.1) 4 (17.4)
9 (14.7) 1 (1.6)
6 (17.1) 0 (0)
13 (32.5) 3 (7.5)
1 (14.2) 1 (14.3)
35 (21.1) 9 (5.4)
ng thoracic aorta; C, distal third of the descending thoracic aorta; D, any
of 126 thoracic aortic aneurysms treated with stent grafts
Procedure- or stent-related
complications, n (%)
Non–stent-related
complications, n (%)
2 (9.5) 2 (9.5)
3 (11.1) 3 (11.1)
19 (24.3) 7 (8.9)
24 (19.0) 12 (9.5)
associated with stent-grafting in patients with thoracic aortic aneurysmsty, in
endo
(%)
)
)
)
)
cendieter
%)
rtality
in patients with TAAs 50 mm or larger (11.4%; P  .69).
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6 months was 63%  7% (Figure 2).
Discussion
This exhaustive study of 166 patients undergoing stent-graft
repair of TAD provides useful insights into the short-term
postoperative outcome. Like previous studies,13-17 our find-
Figure 1. Kaplan-Meier curve depicting the cumulative survival
of the patient cohort with 95% confidence intervals (dotted lines)
and patients at risk for each interval. Survival at 6 months was
86%  6%.
TABLE 9. Complications and treatment failures during the
postoperative period
Complications and treatment failures No. Deaths
Treatment failures
Endoleak 27 0
Stent- or procedure-related complications
Complication related to stent-graft delivery* 14 0
Paraplegia† 6 5
Renal or visceral embolism 5 2
Tracheal or esophageal fistula 3 1
Rupture of thoracic aortic aneurysm 3 3
Migration of stent graft and visceral ischemia 2 1
Cerebral embolism, stroke 2 1
Non–stent-related complications
Acute respiratory failure 4 0
Nosocomial infection 4 0
Myocardial infarction 6 4
Total complications and treatment failures 76 17
There were 27 (16.3%) treatment failures (endoleaks) and 49 complications
in 34 patients (20.5%). Seventeen deaths (10%) occurred, including 13
(7.8%) that were stent or procedure related and 4 (2.2%) that were not
stent related. *Complications related to stent-graft delivery included iliac
artery perforation (n  5) and arterial thrombosis or peripheral embolism
(n  9). †Paraplegia was associated with other major complications in 5
patients, who died.
The Journal of Thoraciings demonstrated that stent-graft repair could provide a less
invasive alternative to conventional open repair. However,
it must be emphasized that follow-up was limited to the
postoperative period.
Only 4 (2.4%) of the 17 deaths in this series were in
direct relation to preoperative patient status. This relatively
low general mortality is especially remarkable insofar as
76% of patients were classified as ASA status III to IV.
Indeed, all 17 deaths (10%) occurred in patients classified as
ASA status III to IV. Only 8 deaths (4.8%) occurred within
the first 30 days, but 9 other patients died as a consequence
of postoperative complications beyond 30 days.
Thirty-five complications were related to the stent graft
or procedure, including 3 ruptures in relation to endoleak, 3
aortoesophageal or tracheal fistulas, and 7 cases of postop-
erative visceral ischemia. Intraoperative stent-graft migra-
tion was observed during deployment in 2 patients with
suboptimal proximal landing zones, and this necessitated
transposition of the left subclavian artery. These 2 compli-
cations provide further evidence of the importance of care-
ful assessment of anatomic features for patient selection.
In addition to the 3 patients who had fatal endoleak-
related rupture, endoleaks were observed in 24 patients.
Type I endoleaks occurred at the proximal landing zone in
patients with a large proximal neck diameter or sharp an-
gulation of the thoracic aorta. A predisposing factor for type
I endoleak was separation and dislocation of modular de-
vices with sharp angulation of the descending thoracic aorta.
The incidence of endoleaks in this series (16.3%) is in
agreement with previous reports17 and emphasizes the im-
Figure 2. Kaplan-Meier curve depicting freedom from failure and
complications, ie, rupture, endoleak, migration, embolism, con-
version, and non–stent-related complications, with 95% confi-
dence intervals (dotted lines) and patients at risk for each inter-
val. The cumulative freedom from failure and complications at 6
months was 63%  7%.portance of patient selection and the need for improving
c and Cardiovascular Surgery ● Volume 131, Number 1 135
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and attachment.18,19
This high rate of stent-related complications is currently
a major limitation for using endovascular repair in low-
operative-risk patients, in whom conventional open repair
usually achieves durable results with a negligible risk of
graft complications or aortic rupture.20,21 However, this
disadvantage may be offset by the lower postoperative
mortality and morbidity of stent-graft repair in comparison
with open surgery.
Paraplegia was observed in only 6 patients (3.6%) in this
study. This rate is similar to that reported by Mitchell and
associates16 in a comparable series. All 6 patients in whom
paraplegia developed in our series had a large aneurysm of
the descending aorta. In 3 cases, stent-graft repair was
associated with concomitant abdominal aortic aneurysm
repair, which was cited as a risk factor for paraplegia in the
Stanford experience.22
Our data indicate that stent-graft repair for type B aortic
dissection has yet to overcome limitations associated with
multiple re-entry tears and flow to aortic branches provided
by the false lumen.23 Mortality after stent-graft repair for
type B aortic dissection was 15.2% in our series, similar to
the results described by Dake and associates.22 These find-
ings contradict previous suggestions that stent-graft repair
for type B dissection has the potential advantages of con-
taining rupture, obliterating the false lumen, and protecting
against the long-term risk of aneurysm.22
Our study suggests that stent-graft repair is a valuable
alternative to emergency surgical replacement for traumatic
pseudoaneurysm. In this subgroup, only 1 patient (5.8%)
died, and none had paraplegia. These rates contrast with
those reported in contemporary series24 using emergency
surgical repair for aortic trauma.
This study shows that stent-graft repair for septic aneu-
rysm is particularly challenging. Two of the 3 patients
treated for septic aneurysm died during the postoperative
period. Despite the publication by Semba and colleagues25
of 2 cases of septic thoracic aneurysm successfully treated
by stent graft, this concept is not substantiated by evidence
even as a bridge to open repair with a homograft.
A disappointing finding of our study was the failure of
some surgeons to apply the basic consensus guidelines,
which recommend surveillance rather than treatment for
thoracic aneurysms smaller than 50 mm.5 Seventeen percent
of the stent-graft procedures, excluding patients with aortic
ulcer and trauma, involved patients with aneurysms smaller
than 50 mm in diameter. Several explanations can be pro-
posed, including overenthusiasm for the short-term benefits
of a new “less-invasive” technology. However, it should be
noted that, as shown in Table 8, mortality from thoracic
aortic aneurysms smaller than 50 mm in diameter (4.7%)
136 The Journal of Thoracic and Cardiovascular Surgery ● Januwas not significantly different (P  .69) from that of tho-
racic aortic aneurysms 50 mm or larger (11.4%).
Several factors may restrict the value of this study,
including its retrospective nature, the absence of a matched
surgical group, short-term follow-up, and use of first- or
second-generation stent grafts. These weaknesses are bal-
anced by the fact that data including complications were
thoroughly collected and cross-checked. Despite these
limitations, it should be said that our data mirror the expe-
rience of other investigators10,13,22 and are comparable to
those of other investigators who used last-generation stent
grafts.14,15,24 This nationwide study demonstrates that stent-
graft repair for TAD can be performed with acceptable
postoperative morbidity.
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